Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells.

Pavlopoulou A., OKTAY Y., Vougas K., Louka M., Vorgias C. E., Georgakilas A. G.

Cancer letters, cilt.380, sa.2, ss.485-493, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 380 Sayı: 2
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/j.canlet.2016.07.018
  • Dergi Adı: Cancer letters
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.485-493
  • Anahtar Kelimeler: Breast cancer stem cells, Chemotherapy, Radiotherapy, Chemoresistance, Radioresistance, Bioinformatics, EPITHELIAL-MESENCHYMAL TRANSITION, HYPOXIA-INDUCIBLE FACTORS, TUMOR-INITIATING CELLS, BOX BINDING PROTEIN-1, DNA-DAMAGE RESPONSE, SELF-RENEWAL, SOLID TUMORS, MULTIDRUG-RESISTANCE, FREE-RADICALS, IN-VITRO
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Breast cancer cells are suggested to be organized in a hierarchical manner with a subpopulation of stem cells, termed as breast cancer stem cells (BCSCs), which contribute significantly to tumorigenesis, cancer recurrence and metastasis. BCSCs haye been demonstrated to exhibit significant resistance to conventional chemo- and radiotherapy. Recent evidence suggests that treatment of breast cancers with radiation or chemotherapy agents induces stem cell-like properties in non-stem cells. Herein, we provide an overview of the key determinants of resistance to chemotherapy and radiation in BCSCs. To this end and by the use of bioinformatics, the molecular pathways, the defining markers, as well as the microenvironmental and genetic factors, which are implicated in the maintenance of sternness, chemo- and radioresistance in BCSCs, are identified and presented. Our findings could provide the foundation for the design of targeted chemo- or radiotherapeutic regimens in order to eliminate or sensitize BCSCs to cytotoxic therapies and prevent tumor relapse and metastasis. (C) 2016 Elsevier Ireland Ltd. All rights reserved.